LACBES
LIVE
Serial Number
79356736
Owner
Shanghai Push Medical Device Co., LTD.Attorney
Xiaofei XueFiling Date
Oct 28, 2022
LACBES Trademark
Serial Number: 79356736 • Registration: 7324511
LACBES is a trademark filed by
Shanghai Push Medical Device Co., LTD.
on October 28, 2022. The trademark is classified under Class 10 (Medical Apparatus).
The application is currently registered and active.
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Xiaofei Xue
706 SE 146th.Ave.
Portland
OR 97233
UNITED STATES
Trademark Details
Filing Date
October 28, 2022
Registration Date
March 12, 2024
Published for Opposition
December 26, 2023
Filing History
FINAL DECISION TRANSACTION PROCESSED BY IB
Nov 2, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Oct 14, 2024 FICS
FINAL DISPOSITION PROCESSED
Oct 14, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 13, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 12, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 12, 2024 R.PR
NOTIFICATION PROCESSED BY IB
Dec 26, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 26, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 26, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 6, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 6, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 6, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 21, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 2, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 2, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 2, 2023 TROA
REFUSAL PROCESSED BY IB
Sep 25, 2023 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 5, 2023 RFCS
REFUSAL PROCESSED BY MPU
Sep 5, 2023 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 16, 2023 RFCR
NON-FINAL ACTION WRITTEN
Aug 15, 2023 CNRT
ASSIGNED TO EXAMINER
Aug 14, 2023 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 7, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 3, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 1, 2022 REPR
